Cart
sales@molnova.com
Ezabenlimab
CAS No. 2249882-54-8
Ezabenlimab( —— )
Catalog No. M36792 CAS No. 2249882-54-8
Ezabenlimab (BI-754091) is an anti-PD-1 monoclonal antibody (mAb) with a binding constant (Kd) of 6 nM in CHO cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 490 | In Stock |
|
| 10MG | 787 | In Stock |
|
| 25MG | 1169 | In Stock |
|
| 50MG | 1535 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEzabenlimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionEzabenlimab (BI-754091) is an anti-PD-1 monoclonal antibody (mAb) with a binding constant (Kd) of 6 nM in CHO cells.
-
DescriptionEzabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo.
-
In VitroEzabenlimab inhibits the interaction of PD-1 to PD-L1 and PD-L2 in CHO cells with IC90s of 4.14 nM and 3.98 nM, respectively; and inhibits the interaction of PD-1 to PD-L1 and PD-L2 in cynomolgus with IC90s of 5.61 nM and 7.54 nM, respectively.Ezabenlimab increases IFN-γ secretion in primary human antigen-experienced CD3-positive T cells, with an EC50 value of 0.9 nM.Ezabenlimab (200 nM) has synergistic effect with BI 754111, resulting in further increase of IFN-γ secretion.
-
In VivoEzabenlimab (0.3-30 mg/kg; i.p.; single dose or twice per week or every 3 weeks) inhibits tumor progress and shows comparable anti-tumor activity in hPD-1 knock-in mouse model.Animal Model:hPD-1 knock-in mouse model Dosage:0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg Administration:Intraperitoneal injection; single dose or twice per week or every 3 weeks Result:Showed tumor growth inhibition (TGI) at day 25 dose-dependently of 99%, 101%, 91%, 48%, and 44%, respectively.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2249882-54-8
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zettl M, et al. Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses. Oncoimmunology. 2022 Jun 16;11(1):2080328. ?
molnova catalog
related products
-
Buddlejasaponin IV
Buddlejasaponin IV has analgesic and anti-inflammatory effects, the inhibitions of the expressions of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 by blocking NF-kappaB activation.
-
Quercetin 3-O-6-O-(E...
Antioxidant agent-18 (compound 5) is a flavonol glycoside with antioxidant activity isolated from Ginkgo biloba. Antioxidant agent-18 scavenges DPPH radicals (IC50: 15.8 μM) and reduces cytochrome c (IC50: 14.7 μM).
-
Kaempferol 3,7-di-O-...
Kaempferol-3,7-di-O-β-glucoside (Kaempferol 3,7-diglucoside) is a flavonol from Morettia philaena, It can inhibit α-amylase, α-glucosidase and Acetylcholinesterase. Kaempferol-3, 7-di-o-β-Glucoside has neuroprotective activity and can slow down differentiated neuronal cells SH-SY5Y from Amyloid β peptide-induced damage.
